NEW YORK, July 3, 2026, 19:03 EDT
- U.S. markets closed Friday for the Independence Day holiday. Recursion Pharmaceuticals, Inc. NASDAQ:RXRX was last seen at $3.80 on Thursday, up 3.54%.
- RXRX rose 7.95% for the holiday week. Thursday’s trading hit 32.68 million shares, about 1.92x its 65-day average, according to MarketWatch.
- Ex-director Christopher Gibson filed Form 144s for possible sales of 100,000 shares on July 1 and another 100,000 shares on July 2.
Recursion Pharmaceuticals, Inc. NASDAQ:RXRX closed Thursday at $3.80, gaining 13 cents as the U.S. markets wrapped up early for the holiday week. The stock traded 32.68 million shares, about double its 65-day average of 17.04 million. Nasdaq was closed Friday for Independence Day.
RXRX outperformed major biotech names this week. From the June 26 close to July 2, RXRX gained 8.0%. The SPDR S&P Biotech ETF (NYSEARCA:XBI) was up 3.3%. iShares Biotechnology ETF (NASDAQ:IBB) rose 4.5%. The SPDR S&P 500 ETF Trust NYSEARCA:SPY added 2.2%.
| Security | July 2 close | July 2 move | Week move |
|---|---|---|---|
| Recursion Pharmaceuticals NASDAQ:RXRX | $3.80 | up 3.54% | up 7.95% |
| SPDR S&P Biotech ETF (NYSEARCA:XBI) | $160.46 | added 2.50% | added 3.27% |
| iShares Biotechnology ETF (NASDAQ:IBB) | $195.70 | rose 2.93% | up 4.45% |
| SPDR S&P 500 ETF Trust NYSEARCA:SPY | $744.78 | fell 0.13% | gained 2.17% |
Week move measures change from June 26 close through July 2 close.
The detail to watch is Gibson’s planned sales. Gibson, who co-founded the company and already said he won’t seek another board term after June, filed for possible sales of 100,000 shares on both July 1 and July 2, according to Form 144 filings. In April’s update on board changes, CEO Najat Khan said, “We remain focused on continuity and long-term value creation at Recursion.” Recursion Pharmaceuticals, Inc.
Form 144 gives notice of a planned sale, but doesn’t confirm all planned sales were made. The July 2 notice did show a July 1 sale of 100,000 shares at $366,630.37 under sales from the prior three months, plus 640,440 shares sold during that time for roughly $2.13 million in gross proceeds.
| Filing item | Shares | Value or proceeds | Scale check |
|---|---|---|---|
| Form 144 filing on July 1 signals sale | 100,000 | $366,630.37 total market value | Roughly 0.02% of current shares |
| Form 144 filing on July 2 signals sale | 100,000 | $374,500 total market value | Equals about 0.31% of Thursday’s traded shares |
| July 2 notice lists sales in past three months | 640,440 | Gross proceeds near $2.13 million | Comes to approximately 0.12% of shares out |
That stands out since the flagged insider sales are smaller than the volume the market saw. Recursion listed 524.68 million shares outstanding. On Thursday, 32.68 million shares traded hands. The combined 200,000 shares from the two insider disclosures add up to just 0.6% of Thursday’s trading.
Short interest is the big story here. MarketWatch listed 184.02 million RXRX shares sold short as of June 15, making up 39.11% of the float. That figure is 5.6 times Thursday’s trading volume. So for next week, what matters more than an insider filing is whether this crowded short sees big trading action.
The balance sheet is another part of the rally story. Recursion reported $665.2 million in cash, cash equivalents and restricted cash as of March 31. The company also said its cash runway goes into early 2028 even if it doesn’t raise more funds. With a market cap around $2.02 billion as of Thursday, that cash pile makes up about a third of Recursion’s equity value.
The company is still burning cash. First-quarter revenue was down to $6.5 million from $14.7 million last year. Net loss narrowed though, down to $117.5 million from $202.5 million. Cash operating expense dropped to $85.1 million from $120.2 million. “We are seeing strong momentum and execution across our portfolio,” Khan said in May. GlobeNewswire
Looking at the week ahead, Nasdaq’s normal session starts again on Monday, July 6, open from 9:30 a.m. to 4:00 p.m. ET. On company news, Recursion is keeping its timeline: the REC-4881 regulatory update and more REC-1245 Phase 1 dose-escalation results remain expected in the second half of 2026.
